Catalyst Fixed Asset Turnover from 2010 to 2025

CPRX Stock  USD 23.19  0.77  3.21%   
Catalyst Pharmaceuticals Fixed Asset Turnover yearly trend continues to be fairly stable with very little volatility. Fixed Asset Turnover is likely to outpace its year average in 2025. During the period from 2010 to 2025, Catalyst Pharmaceuticals Fixed Asset Turnover regression line of annual values had r-squared of  0.1 and arithmetic mean of  92.90. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
96.78
Current Value
141.06
Quarterly Volatility
225.03276771
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 376 M or Operating Income of 104.8 M, as well as many indicators such as Price To Sales Ratio of 4.9, Dividend Yield of 0.0 or PTB Ratio of 5.03. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Slightly volatile
   Fixed Asset Turnover   
       Timeline  

Catalyst Fixed Asset Turnover Regression Statistics

Arithmetic Mean92.90
Geometric Mean13.26
Coefficient Of Variation242.24
Mean Deviation112.52
Median10.73
Standard Deviation225.03
Sample Variance50,640
Range915
R-Value0.31
Mean Square Error49,034
R-Squared0.1
Significance0.24
Slope14.66
Total Sum of Squares759,596

Catalyst Fixed Asset Turnover History

2025 141.06
2024 96.78
2023 107.54
2022 59.22
2021 35.42
2020 917.36
2019 101.93

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 96.78  141.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.